



Supplementary Figure S7: S7A Relationship between risk score type and immune molecular typing; **S7B** Analysis of immune function in low- and high-risk groups; **S7C** Correlation analysis between risk score and positive markers related to immunotherapy; **S7D** Analysis of the correlation between risk scores and critical steps of the cancer immunity cycle; **S7E** Immune checkpoint analysis in high- and low-risk

groups; **S7F-L** Susceptibility analysis was performed separately for axitinib, doxorubicin, gemcitabine, pazopanib, sorafenib, sunitinib, and temsirolimus in high- and low-risk groups.